Jci_page_head_homepage_01 Jci_page_head_homepage_02
Rosa Bacchetta, Laura Passerini, Eleonora Gambineri, Minyue Dai, Sarah E. Allan, Lucia Perroni, Franca Dagna-Bricarelli, Claudia Sartirana, Susanne Matthes-Martin, Anita Lawitschka, Chiara Azzari, Steven F. Ziegler, Megan K. Levings, Maria Grazia Roncarolo
Published in Volume 116, Issue 6
J Clin Invest. 2006; 116(6):1713–1722 doi:10.1172/JCI25112
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 5
Suppressive activity of patients’ CD4+ CD25high T cell lines.

The ability of CD4+CD25high T cell lines derived from patient 1 (Treg Pt1), patient 2 (Treg Pt2), patient 2bis (Treg Pt2b), or an ND (Treg ND) to suppress CD4+CD25 responders from either allogeneic ND-derived T cell line (left panels) or autologous T cell line (right panels) was assessed. Percentages indicate inhibition of proliferation. Data shown are representative of 3 independent experiments.